kti – -Translation – Keybot Dictionary

Spacer TTN Translation Network TTN TTN Login Deutsch Français Spacer Help
Source Languages Target Languages
Keybot 6 Results  www.biozentrum.unibas.ch
  Biozentrum: News Details  
Show textShow cached sourceOpen source URL
Das von der KTI-geförderte Projekt ist aus Hee’s Forschungen in den Gruppen von Prof. Tilman Schirmer und Prof. Urs Jenal hervorgegangen. Die beiden Professoren werden den zukünftigen Jungunternehmern auf ihrem Weg in die Selbstständigkeit mit Rat und Tat zur Seite stehen.
Compare text pagesCompare HTM pagesOpen source URLOpen target URLDefine biozentrum.unibas.ch as primary domain
The CTI-funded project has emerged from Hee’s research in the groups of Prof. Tilman Schirmer and Prof. Urs Jenal. The two professors will advise and support the future entrepreneurs on their way to self-employment.
  Biozentrum: News Details  
Show textShow cached sourceOpen source URL
Die Kommission für Technologie und Innovation (KTI) fördert das Projekt «Therapeptix» von Dr. Chee-Seng Hee und Dr. Christoph Schmutz vom Biozentrum der Universität Basel mit einer Summe von 350‘000 Schweizer Franken.
Compare text pagesCompare HTM pagesOpen source URLOpen target URLDefine biozentrum.unibas.ch as primary domain
The Commission for Technology and Innovation (CTI) is funding the project “Therapeptix”, initiated by Dr. Chee-Seng Hee and Dr. Christoph Schmutz at the Biozentrum of the University of Basel, with 350,000 Swiss francs. During the study, the scientists are developing a new drug to combat bacterial biofilms in the lungs of cystic fibrosis patients. So now, two more Biozentrum researchers embark on the path to self-employment and the establishment of a spin-off.
  Biozentrum: News Details  
Show textShow cached sourceOpen source URL
Vom therapeutischen Potenzial konnten die Jungunternehmer in Zusammenarbeit mit ihren wissenschaftlichen Kooperationspartnern auch die Kommission für Technologie und Innovation (KTI) sowie die Schweizer Krebsliga überzeugen, von denen sie in den nächsten Jahren finanzielle Unterstützung erhalten werden.
Compare text pagesCompare HTM pagesOpen source URLOpen target URLDefine biozentrum.unibas.ch as primary domain
As a start-up company, Simon Ittig and his colleagues have a great interest in continuing to optimize their new technique. Because the researchers and company founders have a specific goal in mind: To further develop the system so that it can also be applied for therapeutic purposes. Using a cancer model they plan to investigate whether T3P technology can be applied to attack cancer cells selectively. In regard to its therapeutic potential, the young entrepreneurs together with their research partners were also able to convince the Commission for Technology and Innovation (CTI) and the Swiss Cancer League which provide financial support in the coming years.
  Biozentrum: News Details  
Show textShow cached sourceOpen source URL
Ziel der mit 350‘000 Schweizer Franken geförderten KTI-Machbarkeitsstudie «Therapeptix» ist die Entwicklung eines Wirkstoffes zur Bekämpfung von bakteriellen Biofilmen in der Lunge von Mukoviszidose-Patienten.
Compare text pagesCompare HTM pagesOpen source URLOpen target URLDefine biozentrum.unibas.ch as primary domain
Early next year, Dr. Chee-Seng Hee and Dr. Christoph Schmutz, from the Biozentrum of the University of Basel, will take the first steps in their venture to self-employment. The aim of the CTI feasibility study ”Therapeptix”, financially supported with funds of 350,000 Swiss francs, is the development of a drug to combat bacterial biofilms in the lungs of cystic fibrosis patients. The findings will serve the basis for establishing a spin-off, to finally bring the drug to the market. Along with their funding, the two research scientists will receive further support in the form of mentoring and coaching programs. And while the technology transfer organization Unitectra supports them around patenting matters, the Biozentrum will provide them with lab space and the required infrastructure.
  Biozentrum: News Details  
Show textShow cached sourceOpen source URL
Hier setzt nun das KTI-Projekt an. «In den Bakterien wird die Bildung von Biofilmen durch verschiedene Signalwege reguliert», erklärt Hee. «Wir haben ein Peptid entdeckt, das in diese Signalwege eingreift und somit die Bildung von Biofilmen verhindert. So bleiben die Infektionserreger für eine antibiotische Therapie empfänglich.» In Kooperation mit Forschern des Universitätsspitals Basel möchten Hee und Schmutz nun einen Wirkstoff entwickeln, der in späteren präklinischen Studien auf seine Wirksamkeit im Organismus getestet werden soll.
Compare text pagesCompare HTM pagesOpen source URLOpen target URLDefine biozentrum.unibas.ch as primary domain
Here is where the CTI project comes into action. “In the bacteria, biofilm formation is regulated by several signaling pathways”, explains Hee. “We have discovered a peptide that intercepts these pathways, thus preventing the formation of biofilms. This means that the pathogens remain susceptible to antibiotic therapy.” In the cooperation with researchers from the University Hospital Basel, Hee and Schmutz aim to develop a drug candidate for pre-clinical testing of its effectiveness in organisms. But the potential applications are thus not yet exhausted. As bacterial biofilms found in catheters and other medical devices are often responsible for the increasing number of hospital infections, which are difficult to treat, such peptide drugs could prove to have a valuable role in this area.
  Biozentrum: News Details  
Show textShow cached sourceOpen source URL
Darüber hinaus haben Forscher des Biozentrums erst vor kurzem die Biotech-Firmen «Nuomedis AG» und «T3Pharmaceuticals» gegründet. Auch sie wurden durch die KTI gefördert und sind nun auf dem Weg ihre Ideen aus der Grundlagenforschung in Richtung Anwendung und Marktreife weiterzuentwickeln.
Compare text pagesCompare HTM pagesOpen source URLOpen target URLDefine biozentrum.unibas.ch as primary domain
"Therapeptix" is not the first spin-off idea that has emerged at the Biozentrum. About fifteen years ago Santhera CEO Dr. Thomas Meier founded here the first spin-off company MyoContract from which “Santhera Pharmaceuticals” arose as the result of a merger. The company is specialized in the development and marketing of drugs for the treatment of rare neuromuscular and mitochondrial diseases and has recently achieved a great success by receiving EU approval for the drug Raxone. In addition, researchers at the Biozentrum have founded the biotech companies “Nuomedis AG” and “T3 Pharmaceuticals”. They also received support from the CTI and are now on the way to develop their ideas from basic research toward applications and marketability. “Nuomedis” is working on a new nanotechnology device for cancer diagnostics, while “T3 Pharmaceuticals” is optimizing a bacterial injection apparatus, to use as a tool to deliver diverse proteins into cells. This apparatus could possibly be applied to also fight tumor cells. Through actively supporting the researchers in the implementation of spin-off projects and the founding of a company, the Biozentrum and the University of Basel are promoting the economic and innovative strength of Switzerland.